Clinical ResearchHIV and Heart DiseaseEndothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s
Key Words
Abbreviations and Acronyms
Cited by (0)
This multicenter trial was conducted by the AIDS Clinical Trials Group (ACTG) funded by the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute. Pharmaceutical support was provided by Abbott Laboratories and Bristol-Myers Squibb Company. The following additional grants were received: NIH AI069424, AI56933, and AI069428 (to Dr. Currier); NIH AI25859, HL72711, RR00750, and RR000750 (to Dr. Dubé); NIH AI069513 (to Dr. Fichtenbaum); NIH AI34853, RR16467, and MD000173 (to Dr. Gerschenson); NIH AI069471 (to Dr. Murphy); NIH AI38855 and AI068634 (to Ms. Komarow); NIH AI38855 and AI068634 (to Dr. Parker); NIH RR16176 and AI25915 (to Dr. Stein); NIH AI69432 (to Dr. Torriani); and NIH AI38558 and NIH AI068636 (to the ACTG leadership). Dr. Torriani is on the advisory board for Abbott. Dr. Currier has received research grants from Merck and Co., Tibotec, GlaxoSmithKline, Theratechnologies, and Schering-Plough; has received honoraria from Gilead, Koronnis, Achillion, and Vertex; and has been a consultant/advisory board member for Bristol-Myers Squibb, Pfizer, Merck, and Gilead. Dr. Dubé has received research grants from Abbott and Bristol-Myers Squibb and has been a consultant to GlaxoSmithKline, Tibotec, Gilead, Bristol-Myers Squibb, and Abbott. Dr. Fichtenbaum has received research grants from Abbott and Bristol-Myers Squibb; has been on the Speakers' Bureaus of Abbott, Bristol-Myers Squibb, and Gilead; and has received honoraria from Abbott, Bristol-Myers Squibb, and Gilead. Dr. Murphy has received research grants from Bristol-Myers Squibb and has been a consultant/advisory board member for Gilead and Bristol-Myers Squibb. Dr. Squires has received a research grant from Bristol-Myers Squibb; has received honoraria from Gilead Sciences, Bristol-Myers Squibb, and Abbott; and has been on the advisory board for Bristol-Myers Squibb, Gilead Sciences, and Abbott. Dr. Stein has received a research grant from Bristol-Myers Squibb and has been a consultant for Abbott. Joseph A. Vita, MD, served as Guest Editor for this article.